But there are many EGFR mutations that affect treatment ... below 0.1% for some targets and observed mutations not identified by NGS,” says Madic 1. The Naica™ System comprises a pressurized ...

Metropolis molecular genomics study shows genetic profiling are improving survival rates: Our Bureau, Bengaluru Friday, November 22, 2024, 14:45 Hrs [IST] Metropolis Healthcare co ...

Kirti Chadha, Chief Scientific and Innovation Officer & Senior Oncopathologist, Metropolis Healthcare, said, “Studying ...

The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.